# Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/deucravacitinib-versus-placebo-and-apremilast-in-moderate-to-severe-plaque/

## Facts

| Field | Value |
| --- | --- |
| Author Names | April W. Armstrong,Melinda Gooderham,Richard B. Warren,Kim Papp,Bruce Strober,Diamant Thaçi,Akimichi Morita,Jacek C. Szepietowski,Shinichi Imafuku,Elizabeth Colston,John Throup,Sudeep Kundu,Steve Schoenfeld,Misti Linaberry,Subhashis Banerjee,Andrew Blauvelt |
| Citations | 354 |
| DOI | 10.1016/j.jaad.2022.07.002 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.jaad.2022.07.002 |
| OpenAlex ID | https://openalex.org/W4284989117 |
| PMID | 35820547 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Melinda Gooderham](https://scholariq.org/researchers/melinda-gooderham/)
- [Bruce Strober](https://scholariq.org/researchers/bruce-strober/)

## Paper primary topic

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Paper topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.